Lexicon Pharmaceuticals’ (LXRX) Market Perform Rating Reiterated at Leerink Partners

Leerink Partners reiterated their market perform rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research report sent to investors on Tuesday, Marketbeat.com reports. Leerink Partners currently has a $1.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $2.00.

Several other research analysts have also weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $2.50.

Lexicon Pharmaceuticals Stock Up 9.4 %

Shares of Lexicon Pharmaceuticals stock opened at $0.37 on Tuesday. The business’s 50 day simple moving average is $0.73 and its 200 day simple moving average is $1.15. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.83. The firm has a market cap of $90.54 million, a PE ratio of -0.49 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. The business had revenue of $26.55 million for the quarter, compared to analyst estimates of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. On average, analysts predict that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LXRX. Bayesian Capital Management LP acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $31,000. RPO LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $33,000. Renaissance Technologies LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $38,000. Arizona State Retirement System increased its holdings in shares of Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 16,136 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in shares of Lexicon Pharmaceuticals by 60.3% during the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 24,615 shares during the last quarter. 74.70% of the stock is owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.